Caren Deardorf - Net Worth and Insider Trading
Caren Deardorf Net Worth
The estimated net worth of Caren Deardorf is at least $9,628 dollars as of 2024-11-10. Caren Deardorf is the Chief Commercial Officer of Magenta Therapeutics Inc and owns about 13,762 shares of Magenta Therapeutics Inc (MGTA) stock worth over $9,628. Details can be seen in Caren Deardorf's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Caren Deardorf has not made any transactions after 2021-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Caren Deardorf
Caren Deardorf Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Caren Deardorf owns 2 companies in total, including Crinetics Pharmaceuticals Inc (CRNX) , and Magenta Therapeutics Inc (MGTA) .
Click here to see the complete history of Caren Deardorf’s form 4 insider trades.
Insider Ownership Summary of Caren Deardorf
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals Inc | 2022-03-11 | director |
| MGTA | Magenta Therapeutics Inc | 2021-09-16 | Chief Commercial Officer |
Caren Deardorf Latest Holdings Summary
Caren Deardorf currently owns a total of 1 stock. Caren Deardorf owns 13,762 shares of Magenta Therapeutics Inc (MGTA) as of September 16, 2021, with a value of $9,628.
Latest Holdings of Caren Deardorf
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MGTA | Magenta Therapeutics Inc | 2021-09-16 | 13,762 | 0.70 | 9,628 |
Holding Weightings of Caren Deardorf
Caren Deardorf Form 4 Trading Tracker
According to the SEC Form 4 filings, Caren Deardorf has made a total of 1 transactions in Magenta Therapeutics Inc (MGTA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Magenta Therapeutics Inc is the sale of 6,238 shares on September 16, 2021, which brought Caren Deardorf around $41,982.
Insider Trading History of Caren Deardorf
- 1
Caren Deardorf Trading Performance
Caren Deardorf Ownership Network
Ownership Network List of Caren Deardorf
Ownership Network Relation of Caren Deardorf
Caren Deardorf Owned Company Details
What does Crinetics Pharmaceuticals Inc do?
Who are the key executives at Crinetics Pharmaceuticals Inc?
Caren Deardorf is the director of Crinetics Pharmaceuticals Inc. Other key executives at Crinetics Pharmaceuticals Inc include Chief Development Officer Dana Pizzuti , See Remarks Marc Wilson , and Chief Scientific Officer Stephen F. Betz .
Crinetics Pharmaceuticals Inc (CRNX) Insider Trades Summary
Over the past 18 months, Caren Deardorf made no insider transaction in Crinetics Pharmaceuticals Inc (CRNX). Other recent insider transactions involving Crinetics Pharmaceuticals Inc (CRNX) include a net sale of 40,035 shares made by Stephen F. Betz , a net sale of 159,049 shares made by Marc Wilson , and a net sale of 91,672 shares made by Dana Pizzuti .
In summary, during the past 3 months, insiders sold 46,410 shares of Crinetics Pharmaceuticals Inc (CRNX) in total and bought 0 shares, with a net sale of 46,410 shares. During the past 18 months, 913,970 shares of Crinetics Pharmaceuticals Inc (CRNX) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 908,970 shares.
Crinetics Pharmaceuticals Inc (CRNX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Crinetics Pharmaceuticals Inc Insider Transactions
Caren Deardorf Mailing Address
Above is the net worth, insider trading, and ownership report for Caren Deardorf. You might contact Caren Deardorf via mailing address: C/o Magenta Therapeutics, Inc., 100 Technology Square, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
